Following a NASH crash, Conatus turns the keys over to regenerative med player
Six months after Conatus execs read last rites over their Novartis-partnered NASH program, they’ve handed the shell of what’s left to a regenerative med …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
